GPR139 has been proposed to have a role as a therapeutic target in schizophrenia, addiction and metabolic disorders, and attention-deficit/hyperactivity disorder, as well as Parkinson’s disease and phenylketonuria [44]. This evidence concerns the gene GPR139 and schizophrenia.